Program

Sunday 15 October 2017

7.30 -08.30 AMRegistration
8.30 AM

Workshop opening
Rob Aarnoutse, PharmD, PhD 
- Radboud University Medical Center, Netherlands

Session 1: Pharmacokinetics & Pharmacodynamics of New & Repurposed TB Drugs
Chairs: Rob Aarnoutse & Rovina Ruslami
8.45 AM

Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy
Khisi Mdluli, PhD - TB Alliance, USA

 Abstract presentations
9.15 AM

Exposure-Response Analysis of Lee 1810, a Lead Spectinamide Antibiotic in Mycobacterium tuberculosis Infected Mice
Santosh Wagh - University of Tennessee Health Science Center, USA

9.30 AMImproved efficacy of a cofactor-independent InhA inhibitor revealed by the C3HeB/ FeJ mouse model
Gregory Robertson - Colorado State University, USA
9.45 AMPharmacokinetic modeling and simulation of pretomanid in pulmonary tuberculosis patients
Michael Lyons - Colorado State University, USA
10.00 AMHigh dose rifampicin for the treatment of TB meningitis: a dose finding study
Rob Aarnoutse - Radboud University Medical Center, Netherlands
10.15 AM Discussion
10.30 AMCoffee Break
Session 2: Pharmacokinetics & pharmacodynamics of approved TB drugs
Chairs: Gerry Davies & Paolo Denti
11.00 AM

A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents
Alexander Berg, PharmD, PhD, FCP, - Critical Path Institute; Tucson, USA

 Abstract presentations
11.30 AM Optimizing the Dose of Levofloxacin: Pharmacokinetic Results from the Opti-Q Study
Charles Peloquin - University of Florida, USA
11.45 AMOtotoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis
Mohammed Aslshaer - University of Florida, USA
12.00 PMPyrazinamide sterilizes necrotic lesions in tuberculosis infected lungs
Veronique Dartois - Rutgers University, USA
12.15 PMMoxifloxacin as the fluoroquinolone of choice to treat TB?
Jansy Sarathy - Rutgers University, USA
12.30 PM Discussion
12.45 PMLunch
13.30 PM                Guided Poster Session
  
Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling
Chairs: Khisi Mdluli & Dakshina Chilukuri
2.00 PM

Benefits of data collaboration – personalized tailoring regimens
Rada Savic, PharmD, PhD - University of California, USA

 Abstract presentations
2.30 PMPharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines
Paolo Denti - University of Cape Town, South Africa
2.45 PMPrediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling
Robin Svensson- Uppsala University, Sweden
3.00 PMRelating rifampicin exposure to treatment response in patients with pulmonary tuberculosis – potential for treatment shortening with higher doses
Elin Svensson- Radboud University Medical Center, Netherlands
3.15 PMPopulation Pharmacokinetic Modeling of Clofazimine in Adult Tuberculosis
Patients: Implications for Dosing
Stella Belonwu - University of California, USA
3.30 PM Discussion
3.45 PMCoffee Break
Session 4: Drug development and optimization: approaches and tools
Chairs: Eric Nuermberger & Charles Peloquin
4.15 PM

Translation of pre-clinical models to clinical outcomes
Tawanda Gumbo, MD, - Baylor Institute for Immunology Research, USA

 Abstract presentations
4.45 PMQuantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens
JF Marier - Certara, Canada
5.00 PMInfluence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis
Kristina Bigelow - Johns Hopkins University, USA
5.15 PMA pharmacokinetic/pharmacodynamic drug-drug interaction study of rifampicin and metformin in type II diabetic tuberculosis patients
Lindsey te Brake - Radboud University Medical Center, Netherlands
5.30 PMPersonalized tuberculosis treatment through Bayesian dosing of rifampicin
Stijn van Beek - Radboud University Medical Center, Netherlands
5.45 PM Discussion
6.00 PMReception
7.00 PMDinner